

AMENDMENTS TO THE CLAIMS

1. (Original) A process for preparing a paroxetine hydrochloride hydrate, comprising reacting (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxyethyl]piperidine with hydrogen chloride in the presence of water, and crystallizing crystals from the resulting reaction mixture in the presence of water.
2. (Original) The process for preparing a paroxetine hydrochloride hydrate according to claim 1, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxyethyl]piperidine is reacted with hydrogen chloride in the presence of water, and crystals are allowed to crystallize from the resulting reaction mixture, without removing the water used in the reaction.
3. (Original) The process for preparing a paroxetine hydrochloride hydrate according to claim 1 or 2, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxyethyl]piperidine is reacted with hydrogen chloride in the presence of water, and allowing crystals to crystallize from the resulting reaction mixture as they are.
4. (Currently Amended) The process for preparing a paroxetine hydrochloride hydrate according to ~~any one of claims 1 to 3~~ claim 1, wherein the (3S, 4R)-1-tert-

butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxymethyl]piperidine is reacted with hydrogen chloride in an aromatic hydrocarbon-based organic solvent by adding hydrochloric acid to the solvent.

5. (Original) The process for preparing a paroxetine hydrochloride hydrate according to claim 4, wherein the aromatic hydrocarbon-based organic solvent is toluene.

6. (Currently Amended) The process for preparing a paroxetine hydrochloride hydrate according to ~~any one of claims 1 to 3~~ claim 1, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxymethyl]piperidine is reacted with hydrogen chloride in a solvent composed only of water.

7. (Currently Amended) The process for preparing a paroxetine hydrochloride hydrate according to claim 1, ~~2, 3 or 6~~, wherein the (3S, 4R)-1-tert-butoxycarbonyl-4-(4-fluorophenyl)-3-[(3,4-methylenedioxy)phenoxymethyl]piperidine is reacted with hydrochloric acid.

8. (Currently Amended) A paroxetine hydrochloride hydrate prepared by a process of ~~any one of claims 1 to 7~~ claim 1.

9. (Currently Amended) A pharmaceutical composition for treating and/or preventing a disorder selected from the group consisting of alcoholism, anxiety syndrome, depression, obsessive-compulsive disorder, panic disorder, chronic pain, obesity, senile dementia, migraine, polyphagia, inappetence, social phobia, premenstrual tension syndrome, adolescent depression, trichotillomania, dysthymia and substance abuse, comprising a paroxetine hydrochloride hydrate prepared by a process of ~~any one of claims 1 to 7~~ claim 1, and a pharmaceutically acceptable carrier.